×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

Ò©Îï·¢Ã÷ÖеÄÌôÕ½Ö®Ò»ÊÇʶ±ð¸ßÖÊÁ¿µÄÏȵ¼»¯ºÏÎï¡£´ËÑо¿ÖÐPKЧ¹ûÅú×¢L12¿É×÷ΪÕë¶ÔPDE5µÄÏȵ¼»¯ºÏÎ½øÒ»²½Ñо¿ºÍ¿ª·¢¡£L12µÄPKÆÊÎöͨ¹ý×ðÁú¿­Ê±¾ÙÐÐ

2023-07-06
|
»á¼ûÁ¿£º

33.jpg

Scaffold hopping refers to computer-aided screening for active compounds with different structures against the same receptor to enrich privileged scaffolds, which is a topic of high interest in organic and medicinal chemistry. One of the biggest challenges in drug discovery is to identify high-quality hit and lead compounds. Lead L12 had an IC50 of 8.7 nM and exhibited a different binding pattern in its crystal structure with PDE5 from the famous starting drug tadalafil, and PK results indicate that L12 could be used as a promising lead for further development. Pharmacokinetic properties of L12 were analyzed by Medicilon.

Reference:

Deyan Wu, et al. Free energy perturbation (FEP)-guided scaffold hopping. Acta Pharm Sin B. 2022 Mar;12(3):1351-1362. doi: 10.1016/j.apsb.2021.09.027. 

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿